Medical Discovery NewsBridging the World of Medical Discovery and You

Recent Episodes

Sweet Guts

MP3 WAV

To everyone's surprise three years ago, scientists discovered our sugar receptors aren't exclusive to the tongue. Our guts can sense sweetness too – the stomach, intestine, pancreas, and even our airways.

Scientists got pretty excited about what this meant for diabetics. Could drugs target these receptors to help people with type 2 diabetes? This is the most common form of diabetes when the body no longer makes enough insulin or stops responding to it. We need insulin for our cells to take up the glucose in our blood and use it for energy.

One drug, called New-Met is promising. It's now in phase two clinical trials and targets receptors in the intestine. New-Met binds to sweet receptors there, activating the release of incretins. Incretins stimulate the release of insulin which then allows our cells to take up sugar in the blood. This mimics the natural signaling process triggered by sugars and it's fast and direct.

Discovering this signaling process in the intestine cleared up a fifty year mystery: how eating glucose triggers significantly more insulin than injecting it directly into the bloodstream. When the sweet receptors in the intestine detect sugar they trigger adjacent cells to make a glucose transporter to take the sugar into cells. The faster the sugar is absorbed, the more signals are sent to the pancreas and more insulin is released.

Thus, understanding these alternative taste receptors can help us develop effective therapies. New-Met will also help the four million diabetics in the US who can't take metformin, the leading type-2 diabetes drug. As the number of Americans with diabetes climbs to six million, the demand for additional medications will rise with them.

More Information

Neuroscience: Hardwired for taste
Nature —A mouthful of bittersweet chocolate cake with a molten centre can trigger potent memories of pleasure, lust and even love. But all it takes is one bad oyster to make you steer clear of this mollusc for life. Neuroscientists who study taste are just beginning to understand how and why the interaction of a few molecules on your tongue can trigger innate behaviours or intense memories.

Elcelyx 'Guts' Conventional Thinking on Metformin
BioWorld —A San Diego biotech with eight employees grabbed the spotlight at the American Diabetes Association (ADA) Scientific Sessions in Chicago with the revelation that Type II diabetes drug metformin acts in the lower bowel, not in the bloodstream.

Metformin in the treatment of adults with type 2 diabetes mellitus
UpToDate — Two classes of oral hypoglycemic drugs directly improve insulin action: biguanides (only metformin is currently available) and thiazolidinediones (TZDs). In the absence of contraindications, metformin is considered the first choice for oral treatment of type 2 diabetes (table 1). A 2006 consensus statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), updated in 2009 and 2012, proposed that metformin therapy (in the absence of contraindications) be initiated, concurrent with lifestyle intervention, at the time of diabetes diagnosis [1-3].

 Medicine...

Medicine is constantly advancing – that is a great thing about life in the 21st century. But it doesn’t just happen. Dedicated biomedical scientists are making discoveries that translate into those new medical advances.

Biomedical science is broad, encompassing everything from social science to microbiology, biochemistry, epidemiology, to structural biology and bioinformatics to name just a few areas. And, it can involve basic fundamental biology, the use of AI and chemistry to clinical studies that evaluate new medicines in patients.

No matter the research focus, the goal is always the same, to advance human health. It may take a few months, a few years or for fundamental science, a few decades. Few people make the connection that biomedical science is medicine and that biomedical scientists are working today on the medicine of tomorrow. Our weekly 500-word newspaper columns and 2-minute radio shows and podcasts provide insights into a broad range of biomedical science topics.

Medical Discovery News is dedicated to explaining discoveries in biomedical research and their promise for the future of medicine.

Podcasts

Alternatively, you can copy and paste the following web address (URL) into iTunes as a new subscription:
https://www.medicaldiscoverynews.com/shows/audio/mdnews.rss

You can also search and subscribe to "Medical Discovery News" in the podcast section of iTunes.

See all podcasts and radio stations

The www.medicaldiscoverynews.com web site and Medical Discovery News radio program (Program) are made possible by The University of Texas Medical Branch at Galveston (UTMB)as a community service and are intended to advance UTMB's mission of providing scholarly teaching, innovative scientific investigation, and state-of-the-art patient care in a learning environment to better the health of society and its commitment to the discovery of new innovative biomedical and health services knowledge leading to increasingly effective and accessible health care for the citizens of Texas.

All information provided on the web site and in the Program is for informational purposes only and is not intended for use as diagnosis or treatment of a health problem or as a substitute for consulting a licensed medical professional. Any information obtained by participating as a web site visitor or program listener is not intended to and should not be considered to constitute medical advice.

Thoughts and opinions expressed on the Program or on the website are those of the authors or guests and do not necessarily reflect the opinions of UTMB. The provision of links to other websites is not to be construed as written or implied sponsorship or endorsement of such websites by UTMB.

Please contact Dr. David Niesel or Dr. Norbert Herzog via email with any concerns, suggestions or comments.

All rights are reserved to information provided on the website or other information sources. No part of these programs can be reproduced stored in a retrieval system or transcribed in any form or by any means for personal or financial gained without the express written permission of Drs. Niesel and Dr. Herzog.